These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29247835)

  • 1. Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
    Banning A; Schiff M; Tikkanen R
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):668-675. PubMed ID: 29247835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria.
    Banning A; Gülec C; Rouvinen J; Gray SJ; Tikkanen R
    Sci Rep; 2016 Nov; 6():37583. PubMed ID: 27876883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
    Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
    Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
    Saarela J; von Schantz C; Peltonen L; Jalanko A
    Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ser72Pro active-site disease mutation in human lysosomal aspartylglucosaminidase: abnormal intracellular processing and evidence for extracellular activation.
    Peltola M; Tikkanen R; Peltonen L; Jalanko A
    Hum Mol Genet; 1996 Jun; 5(6):737-43. PubMed ID: 8776587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production.
    Banning A; König JF; Gray SJ; Tikkanen R
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
    Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
    Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissection of the molecular consequences of a double mutation causing a human lysosomal disease.
    Riikonen A; Ikonen E; Sormunen R; Lehto VP; Peltonen L; Jalanko A
    DNA Cell Biol; 1994 Mar; 13(3):257-64. PubMed ID: 8172656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies.
    Banning A; Laine M; Tikkanen R
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assignment of the aspartylglucosaminidase gene (AGA) to 4q33----q35 based on decreased activity in a girl with a 46,XX,del(4)(q33) karyotype.
    Engelen J; Hamers A; Schrander-Stumpel C; Mulder H; Poorthuis B
    Cytogenet Cell Genet; 1992; 60(3-4):208-9. PubMed ID: 1505217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and structural insights into an allelic variant causing the lysosomal storage disorder - aspartylglucosaminuria.
    Pande S; Bizilj W; Guo HC
    FEBS Lett; 2018 Aug; 592(15):2550-2561. PubMed ID: 29993127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of a point mutation that causes the genetic disease aspartylglucosaminuria.
    Sui L; Lakshminarasimhan D; Pande S; Guo HC
    Structure; 2014 Dec; 22(12):1855-1861. PubMed ID: 25456816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a point mutation in aspartylglucosaminidase gene: evidence for a readthrough of a translational stop codon.
    Peltola M; Chiatayat D; Peltonen L; Jalanko A
    Hum Mol Genet; 1994 Dec; 3(12):2237-42. PubMed ID: 7881426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A family with two children diagnosed with aspartylglucosaminuria-case report and literature review].
    Liu Y; Zou L; Meng Y; Zhang Y; Shi X; Ju J; Yang G; Hu L; Chen X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):455-9. PubMed ID: 25190167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartylglucosaminuria caused by a novel homozygous mutation in the AGA gene was identified by an exome-first approach in a patient from Japan.
    Yamamoto T; Shimojima K; Matsufuji M; Mashima R; Sakai E; Okuyama T
    Brain Dev; 2017 May; 39(5):422-425. PubMed ID: 28063748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
    Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
    Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation.
    Ikonen E; Enomaa N; Ulmanen I; Peltonen L
    Genomics; 1991 Sep; 11(1):206-11. PubMed ID: 1765378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
    Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
    J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.